Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy

Immunocheckpoint inhibitors have shown significant efficacy in the treatment of hepatocellular carcinoma (HCC), but there are individual differences. The aim of this study was to explore body mass index (BMI) as a predictor of anti-PD-1 efficacy in patients with HCC. We retrospectively analyzed 101...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jierong, Lu, Lianghe, Qu, Chunhua, A, Gari, Deng, Fangqi, Cai, Muyan, Chen, Wei, Zheng, Lie, Chen, Jiewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530364/
https://www.ncbi.nlm.nih.gov/pubmed/36203764
http://dx.doi.org/10.3389/fmed.2022.981001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530364/
https://www.ncbi.nlm.nih.gov/pubmed/36203764
http://dx.doi.org/10.3389/fmed.2022.981001

Ejemplares similares